Recon: FDA rejects Camurus’ rare hormone disorder drug; Amgen to launch Eylea biosimilar in US after appeals court decision
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited States